Maze Therapeutics, Inc.
- MAZE · Nasdaq
- Biological Products, (No Diagnostic Substances)
- South San Francisco, CA
- 141 employees
- CIK 0001842295
Updated from SEC filings through
Top things to know
Executives
- Jason Coloma V. Chief Executive Officer 4, 2026-09-04
- Misbah Tahir Chief Financial Officer 10-K, 2026-03-25
- Harold Bernstein President, R&D & CMO 4, 2026-09-08
- Atul Dandekar CSBO 4, 2026-09-04
- Phillips Courtney GC and Corp. Secretary 4, 2026-09-04
- Amy Bachrodt SVP, Finance 4, 2026-04-02
Maze Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in South San Francisco, CA. It trades as MAZE on Nasdaq. Revenue was $168M in the fiscal year ending December 31, 2024. It reported about 141 employees. Jason Coloma V. is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | Not on file | $168M 10-K, 2026-03-25 |
| Operating income | -$143M 10-K, 2026-03-25 | $57.6M 10-K, 2026-03-25 |
| SG&A | $34.5M 10-K, 2026-03-25 | $26.4M 10-K, 2026-03-25 |
| Net income | -$131M 10-K, 2026-03-25 | $52.2M 10-K, 2026-03-25 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jason Coloma V. | Chief Executive Officer | 4, 2026-09-04 |
| Misbah Tahir CFO at Maze Therapeutics | Chief Financial Officer | 10-K, 2026-03-25 |
| Harold Bernstein | President, R&D & CMO | 4, 2026-09-08 |
| Atul Dandekar | CSBO | 4, 2026-09-04 |
| Phillips Courtney | GC and Corp. Secretary | 4, 2026-09-04 |
| Amy Bachrodt | SVP, Finance | 4, 2026-04-02 |
| Chan ges | in and Disagreements with Accountants on Accounting and Financial Disclosure | 10-K, 2026-03-25 |
| Hervé Hoppenot | Chairperson of our Board of Directors | 10-K, 2026-03-25 |
| Catherine Angell Sohn, Pharm. D. | Director | 10-K, 2026-03-25 |
| Charles Homcy, M.D. | Director | 10-K, 2026-03-25 |
| Daniel Spiegelman | Director | 10-K, 2026-03-25 |
| Jonathan Lim, M.D. | Director | 10-K, 2026-03-25 |
| Nancy C. Andrews, M.D., Ph.D. | Director | 10-K, 2026-03-25 |
| Neil Exter | Director | 10-K, 2026-03-25 |
| Richard Scheller, Ph.D. | Director | 10-K, 2026-03-25 |
Shares and governance
| Shares outstanding | 54.7 million (as of November 4, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $444M (as of June 30, 2025) | 10-K, March 25, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting June 8, 2026 (filed April 28, 2026) | DEF 14A, April 28, 2026 |
| Auditor | Ernst & Young LLP (San Mateo, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 2, 2026 | Jason Coloma V. Chief Executive Officer | Sale | 34,501 | $1.0M | Form 4, November 4, 2026 |
| October 29, 2026 | Atul Dandekar CSBO | Sale | 7,500 | $241K | Form 4, October 30, 2026 |
| October 1, 2026 | Harold Bernstein President, R&D & CMO | Sale | 16,141 | $435K | Form 4, October 2, 2026 |
| October 1, 2026 | Jason Coloma V. Chief Executive Officer | Sale | 34,501 | $932K | Form 4, October 2, 2026 |
| September 29, 2026 | Atul Dandekar CSBO | Sale | 7,500 | $203K | Form 4, October 1, 2026 |
| September 4, 2026 | Harold Bernstein President, R&D & CMO | Sale | 9,705 | $254K | Form 4, September 8, 2026 |
| September 3, 2026 | Harold Bernstein President, R&D & CMO | Sale | 10,295 | $270K | Form 4, September 4, 2026 |
| September 3, 2026 | Atul Dandekar CSBO | Sale | 6,434 | $169K | Form 4, September 4, 2026 |
Recent 8-K events
- 8-K filed 2026-10-16
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-08-17
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-10
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-22
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-22
- Item 8.01 Other events
- 8-K filed 2026-03-25
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-04
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Maze Therapeutics, Inc.
- What does Maze Therapeutics, Inc. do?
- Maze Therapeutics, Inc. is classified by the SEC as Biological Products, (No Diagnostic Substances) (SIC 2836). It is based in South San Francisco, CA.
- What is Maze Therapeutics, Inc.'s revenue?
- $168M for the fiscal year ending December 31, 2024, from its 10-K filed March 25, 2026.
- Is Maze Therapeutics, Inc. profitable?
- Maze Therapeutics, Inc. reported net income of $52.2M for the fiscal year ending December 31, 2024.
- How many employees does Maze Therapeutics, Inc. have?
- About 141 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Maze Therapeutics, Inc.?
- Jason Coloma V., Chief Executive Officer, as named in a 4 filed September 4, 2026.
- Who is the CFO of Maze Therapeutics, Inc.?
- Misbah Tahir, Chief Financial Officer, as named in a 10-K filed March 25, 2026.
- Where is Maze Therapeutics, Inc. headquartered?
- South San Francisco, CA.
- What is Maze Therapeutics, Inc.'s stock ticker?
- MAZE on Nasdaq.
- What industry is Maze Therapeutics, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Maze Therapeutics, Inc.'s website?
- mazetx.com. Investor relations: https://ir.mazetx.com/.
- When does Maze Therapeutics, Inc. report earnings next?
- November 11, 2026. Source: estimate_10q_cadence.
- Is Maze Therapeutics, Inc. a public company?
- Yes. Maze Therapeutics, Inc. files with the SEC under CIK 0001842295 and trades as MAZE.
- Who audits Maze Therapeutics, Inc.?
- Ernst & Young LLP, San Mateo, California, as named in its latest annual report (10-K).
- How many shares of Maze Therapeutics, Inc. are outstanding?
- 54.7 million shares as of November 4, 2026, from its 10-Q filed November 9, 2026.
- What is Maze Therapeutics, Inc.'s public float?
- $444M as of June 30, 2025, as reported on the cover of its 10-K filed March 25, 2026.
- How many business segments does Maze Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Maze Therapeutics, Inc.'s annual shareholder meeting?
- June 8, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.
- Have Maze Therapeutics, Inc. insiders traded stock recently?
- Since December 29, 2025, officers and directors reported 45 open-market sales worth about $25.0M and 0 purchases on Forms 4 and 5. The most recent: Jason Coloma V. (Chief Executive Officer) sold 34,501 shares on November 2, 2026.